

Scottsdale, AZ; Florida Institute for Human & Machine Cognition, Inc., Pensacola, FL; GaitIQ, Inc., San Antonio, TX; GelSana Therapeutics, Inc., Aurora, CO; GeneInfoSec, Boulder, CO; Gener8 LLC, San Jose, CA; Georgetown University, Washington, DC; Ginkgo Bioworks, Inc., Boston, MA; Glendor, Inc., Draper, UT; Grant Halliburton Foundation, Inc., Dallas, TX; Gwen Lily Research Foundation, Irving, TX; Harmony Healthcare Solutions, Inc. dba Harmony Health, Sunnyvale, CA; Healthpointe Solutions, Inc., Austin, TX; HERMTAC LLC, Dallas, TX; ICON Government and Public Health Solutions, Inc., Blue Bell, PA; Inhance Digital Corp., Los Angeles, CA; Innovation Incubator, Inc., Bayside, NY; International Business Machines Corp., Armonk, NY; INVIZA Corp., Malden, MA; IOTAI, Inc., Fremont, CA; Irrational Labs, Oakland, CA; Irving Burton Associates, Silver Springs, MD; JPS Health Network, Fort Worth, TX; Jubilant Hollisterstier LLC, Spokane, WA; Jurata Thin Film, Inc., Chapel Hill, NC; K2 Biolabs, Inc., Houston, TX; Kaibab Health, Sheridan, WY; Knight Technical Solutions LLC, Huntsville, AL; Lazarus 3D, Philomath, OR; Lighthouse XR LLC, Chester, VA; Limax Biosciences, Inc., Somerville, MA; Locus Biosciences, Morrisville, NC; LSU Health Science Center: New Orleans, New Orleans, LA; LSU Health Shreveport, Shreveport, LA; Luna Labs USA LLC, Charlottesville, VA; M3D, Inc., Ann Arbor, MI; MapHabit, Inc., Atlanta, GA; Maravai Lifesciences, San Diego, CA; Maryland Technology Development Corp., Columbia, MD; Mass General Brigham, Somerville, MA; Maxwell Biosciences, Inc., Austin, TX; MDC Studio, Inc., Baltimore, MD; Medable, Palo Alto, CA; MedVector, El Segundo, CA; Mensel, Inc., Fort Worth, TX; Moberg Analytics, Inc., Philadelphia, PA; Molecular Technologies Laboratories LLC, Columbus, OH; MRIGlobal, Gaithersburg, MD; National Association of Community Health Centers, Inc., Bethesda, MD; National Hispanic Health Foundation, Washington, DC; National Resilience, Inc., San Diego, CA; National Strategic Research Institute, Omaha, NE; Neurxstem, Inc., Columbus, OH; New Horizons Diagnostics Corp., Baltimore, MD; NIRSense, Inc., Richmond, VA; North Carolina State University, Raleigh, NC; NXTech, Inc., Patchogue, NY; O3 World LLC, Philadelphia, PA; Oceanit Laboratories, Inc., Honolulu, HI; OLSF Ventures, Tulsa, OK; Oregon Bioscience Association, Portland, OR; Orlando Health, Orlando, FL; Otter Cove Solutions LLC, Gaithersburg, MD; OXOS

Medical, Atlanta, GA; Parkland Center for Clinical Innovation, Dallas, TX; Parkland Health, Dallas, TX; Patchwise Labs, Alameda, CA; Pennington Biomedical Research Center, Baton Rouge, LA; Pennsylvania State University—College of Medicine, Hershey, PA; Phronetik, Inc., Flower Mound, TX; Polaris Sensor Technologies, Inc., Huntsville, AL; PPD Development LP, Wilmington, NC; ppxTEX LLC, Jackson, MS; PragmaClin, St. John's, CANADA; PriMetaz, Boston, MA; Proteios Technology, Inc., Issaquah, WA; Purdue University, West Lafayette, IN; Qana Therapeutics, Inc., Austin, TX; QuantaSpec, Inc., Essex Junction, VT; Re:Build Manufacturing, Framingham, MA; Research Your Health LLC, Plano, TX; Resonantia Diagnostics, Inc., Dallas, TX; Ridgeline Therapeutics, Houston, TX; Ronawk, Inc., Overland Park, KS; Rubitection, Pittsburgh, PA; Rubix LS, Lawrence, MA; Rutgers University, New Brunswick, NJ; Safebeat Rx, Inc., Carson, CA; SafeGuard Surgical, Tampa, FL; SafetySpect, Inc., Grand Forks, ND; Safi Biotherapeutics, Inc., Cambridge, MA; SanaHeal, Inc., Boston, MA; Scorpilus BioManufacturing, San Antonio, TX; Signature Science LLC, Austin, TX; Signum Technologies, Inc., Randor, PA; SimX, Inc., San Francisco, CA; Sonera Magentics, Inc., Berkeley, CA; Southwest Research Institute, San Antonio, TX; Southwest Texas Regional Advisory Council, San Antonio, TX; Sozo Dx LLC, Plano, TX; Sparta Science, San Francisco, CA; SPEAR Human Performance, Inc., Tallahassee, FL; Spectral Platforms, Duarte, CA; Sperry Medtech, Inc., Springfield, MA; Stanford Byers Center for Biodesign, Stanford, CA; Stellarray, Inc., Austin, TX; Swaza, Mountain View, CA; Talis Biomedical Corp., Redwood City, CA; Texas A&M Engineering Experiment Station, Bryan, TX; Texas Biomedical Research Institute, San Antonio, TX; Texas Healthcare and Bioscience Institute, Austin, TX; Texas Oncology, Dallas, TX; Texas State University—Translational Health Research Center, San Marcos, TX; Texas Tech University Health Sciences Center, Lubbock, TX; Texas Woman's University, Denton, TX; The Geneva Foundation, Tacoma, WA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; The Life Raft Group, Wayne, NJ; The Nebraska Medical Center, Omaha, NE; The University of Texas at Dallas, Richardson, TX; The University of Texas: M.D Anderson Cancer Center, Houston, TX; TheraTec, Inc., Horace, ND; TheraVista Health, Brentwood, TN; Thomas Jefferson

University, Philadelphia, PA; Tranexamic Technologies LLC, Dallas, TX; Ubiros, Inc., Natick, MA; University City Science Center, Philadelphia, PA; University of California at Riverside, Riverside, CA; University of Delaware, Newark, DE; University of Hawai'i System, Honolulu, HI; University of Montana, Missoula, MT; University of Nebraska Medical Center, Omaha, NE; University of Notre Dame, Notre Dame, IN; University of Southern California, Los Angeles, CA; University of Texas at Austin, Austin, TX; University of Texas at San Antonio, San Antonio, TX; Univox Technical Solutions LLC dba Univox LLC, Tijeras, NM; Vanderbilt University, Nashville, TN; Varda Space Industries, Inc., El Segundo, CA; VelocityTX, San Antonio, TX; Verily Life Sciences LLC, South San Francisco, CA; ViBo Health, Fairfax, VA; Vivonics, Inc., Bedford, MA; Wake Forest University Health Sciences, Winston Salem, MA; Weinberg Medical Physics, Inc., Rockville, MD; West-Tech Materials, Keller, TX; Yuzu Labs Public Benefit Corp., San Francisco, CA; Zeteo Biomedical LLC, Austin, TX; Zeteo Tech, Inc., Sykesville, MD; Zymeron Corp., Durham, NC.

Consistent with 15 U.S.C. 4301(a)(6)(C), (E) and (F), the CX Hub is a new consortium created in response to requirements of the Advanced Research Projects Agency for Health (ARPA-H) for the active transition of health innovation in an expedient, safe, cost-effective, accessible, and sustainable manner that reaches all Americans. The CX Hub will take a human-centered approach to develop technologies and health solutions that will be accessible, desirable, and affordable for all. It will also take a proactive approach to enhance clinical trials, reach representative patient populations, and capture outcomes data for future use leading to better and more equitable health outcomes for all.

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024-07942 Filed 4-15-24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Material Modification to Consent Decree Under the Clean Water Act

On April 10, 2024, the Department of Justice lodged a proposed material modification to a Consent Decree ("Decree") with the United States District Court for the Eastern District of Kentucky in the lawsuit entitled *United*

States and Commonwealth of Kentucky v. Lexington-Fayette Urban County Government, Civil Action No. 5:06-cv-386-KSF.

The Consent Decree—entered by the court in 2011—resolved alleged violations of the Clean Water Act stemming from Lexington-Fayette Urban County Government’s (“LFUCG”) operation of its sanitary sewer system and wastewater treatment plant. The Decree—including a First Material Modification entered by the court in 2015—required LFUCG to complete remedial projects to its sewer system and wastewater treatment plant to eliminate sanitary sewer overflows by December 31, 2026. The proposed material modification extends the final compliance deadline for remedial projects by four years to December 31, 2030, as well as making changes to reporting frequency and methods.

The publication of this notice opens a period for public comment on the proposed modification. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States and Commonwealth of Kentucky v. Lexington-Fayette Urban County Government*, D.J. Ref. No. 90-5-1-1-08858. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

To submit comments:	Send them to:
By email	pubcomment-ees.enrd@usdoj.gov.
By mail	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.

During the public comment period, the proposed modification, along with the previously entered Consent Decree and First Material Modification, may be examined and downloaded at this Justice Department website: <http://www.justice.gov/enrd/consent-decrees>. If you require assistance accessing the proposed material modification, you may request assistance by email or by mail to the addresses provided above for submitting comments.

Scott D. Bauer,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2024-07935 Filed 4-15-24; 8:45 am]

BILLING CODE 4410-15-P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decree Under the Safe Drinking Water Act

On April 9, 2024, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the Eastern District of California in the lawsuit entitled *United States v. Grindstone Indian Rancheria of Wintun-Wailaki Indians of California*, Civil Action No. 2:24-cv-01044-KJM-CKD.

The proposed Consent Decree would resolve claims against the Grindstone Indian Rancheria of Wintun-Wailaki Indians of California (“Defendant”) arising under sections 1414(g) and 1431 of the Safe Drinking Water Act (“SDWA”), 42 U.S.C. 300g-3(g) and 300i, and the SDWA’s National Primary Drinking Water Regulations at 40 CFR part 141, as well as for its failure to comply with the requirements of two administrative orders issued by the United States Environmental Protection Agency pertaining to Defendant’s noncompliance with the SDWA and its regulations at the Grindstone Indian Rancheria Public Water System. The proposed Consent Decree resolves these claims and includes a civil penalty of \$8,963 and injunctive relief including, but not limited to, demonstrating compliance with surface water treatment requirements, providing boil water notices and alternative water supply, retaining at least two full time operators for the drinking water system, providing annual reporting to its customers, providing operating reports to EPA, and developing and implementing an extensive operation and maintenance plan for the water system.

The publication of this notice opens a period for public comment on the proposed Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States v. Grindstone Indian Rancheria of Wintun-Wailaki Indians of California*, D.J. Ref. No. 90-5-1-1-12322. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

To submit comments:	Send them to:
By email	pubcomment-ees.enrd@usdoj.gov.

To submit comments:	Send them to:
By mail	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.

Any comments submitted in writing may be filed by the United States in whole or in part on the public court docket without notice to the commenter.

During the public comment period, the proposed Consent Decree may be examined and downloaded at this Justice Department website: <https://www.justice.gov/enrd/consent-decrees>. If you require assistance accessing the proposed Consent Decree, you may request assistance by email or by mail to the addresses provided above for submitting comments.

Scott Bauer,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2024-07926 Filed 4-15-24; 8:45 am]

BILLING CODE 4410-15-P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decree Under the Comprehensive Environmental Response, Compensation, and Liability Act

On April 11, 2024, the Department of Justice lodged a proposed consent decree with the United States District Court for the District of New Jersey in the lawsuit entitled *United States, New Jersey Department of Environmental Protection, the Commissioner of the New Jersey Department of Environmental Protection, and the Administrator of the New Jersey Spill Compensation Fund v. PPG Industries, Inc.*, Civil Action No. 2:24-04771.

The United States filed this lawsuit under the Comprehensive Environmental Response, Compensation, and Liability Act (“CERCLA”), on behalf of the U.S. Environmental Protection Agency (“EPA”). The New Jersey Department of Environmental Protection, the Commissioner of the New Jersey Department of Environmental Protection, and the Administrator of the New Jersey Spill Compensation Fund (collectively, “NJDEP”) are co-plaintiffs. PPG Industries, Inc. (“PPG”) is the defendant named in the complaint. The complaint seeks injunctive relief and reimbursement of response costs in connection with the Riverside Industrial